Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Anatomical navigation to guide catheter ablation for atrial fibrillation and flutter

Official title: Anatomical Navigation for Guided Electrophysiology in AFL and AFib

Run by LUMA Vision Ltd. · NCT07210151 · Data updated 2026-11-12

This trial will test whether the VERAFEYE Anatomical Guidance System helps doctors guide catheter ablation in adults with atrial fibrillation or atrial flutter.

More Atrial Fibrillation trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorLUMA Vision Ltd.
Industry-sponsored
Locations4 sites (Split and 3 other locations)
StatusRecruiting
StartedJanuary 29, 2026
Main results expectedDecember 16, 2026
Study endsDecember 16, 2026
Registry record updatedNovember 3, 2026
Trial IDNCT07210151 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age 18+) who are scheduled to undergo catheter ablation for atrial flutter or atrial fibrillation and who can provide informed consent and complete study assessments.

Probably not a fit

Patients for whom placement of the VERAFEYE imaging catheter is technically not feasible, pregnant women, or those with unresolved adverse events from prior procedures are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults scheduled for catheter ablation for atrial flutter, paroxysmal AF, or persistent AF will undergo their planned procedure using the commercial VERAFEYE Anatomical Guidance System. Clinical teams will use the device during mapping and ablation while study staff collect procedural data on how the system is used and immediate procedural outcomes. Data collected will include technical feasibility of catheter placement, acute procedural success metrics, and any procedure-related adverse events. Results will be used to inform refinement and further development of the VERAFEYE system.

Why it matters

Potential benefit: If successful, the system could make mapping and ablation more accurate and efficient, potentially shortening procedures and improving acute success rates.

How similar studies have gone: Other anatomical mapping and intracardiac imaging systems have demonstrated benefit in guiding ablation and reducing fluoroscopy exposure, though VERAFEYE itself is being further characterized in this study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* IC1: Subject is at least 18 years of age at the time of consent
* IC2: Subject is scheduled to undergo a catheter-ablation procedure to treat AFL/AF (\*according to current international and local guidelines and per physician discretion)
* IC3: Subject is able to understand and willing to provide written informed consent
* IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site

Exclusion Criteria:

* EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion
* EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)
* EC3: Unrecovered/unresolved Adverse Events from any previous invasive procedure
* EC4: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure.
* EC5: Life expectancy less than 12 months
* EC6: Current LA thrombus

Note: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.

Where it's running

  • Klinicki Bolnicki Centar (KBC)
    Split, Croatia
    Recruiting
  • Na Homolce Hospital
    Prague, Czechia
    Recruiting
  • Ikem
    Prague, Czechia
    Not yet recruiting
  • Vilnius University Hospital Santaros klinikos
    Vilnius, Lithuania
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.